|
2026 Journal Article Adherens junction dysfunction in intestinal inflammation revisitedHaslam, Fabienne, Begun, Jakob and Yap, Alpha S. (2026). Adherens junction dysfunction in intestinal inflammation revisited. Molecular Biology of the Cell, 37 (10) mbc.E25-09-0426, 1-6. doi: 10.1091/mbc.e25-09-0426 |
|
2026 Journal Article TREAT-TO-TARGET IN INFLAMMATORY BOWEL DISEASE: PROMISE, PERILS, AND THE PATH FORWARDSingh, Siddharth, Nardone, Olga Maria, Allocca, Mariangela, Yuan, Yuhong, Begun, Jakob, Hou, Jason K., Shehab, Mohammad, Kobayashi, Taku, Ahuja, Vineet, Dignass, Axel and Jairath, Vipul (2026). TREAT-TO-TARGET IN INFLAMMATORY BOWEL DISEASE: PROMISE, PERILS, AND THE PATH FORWARD. Clinical Gastroenterology and Hepatology. doi: 10.1016/j.cgh.2026.09.033 |
|
2026 Journal Article Janus kinase inhibitors for acute severe ulcerative colitis: comparing upadacitinib to tofacitinib and rescue to sequential salvage therapyGilmore, R., Fernandes, R., Goetz, N., Chin, S., Con, D., De Cruz, P., Demase, K., Sparrow, M. P., Lucas, S., Garg, M., Tuttle, Z., Clark, N., Tassone, D., Ding, N., Loebenstein, M., Nguyen, A., Moore, G. T., Thin, L., MacFarlane, K., Lynch, K. D., Subhaharan, D., Mohsen, W., Haig, A., Day, M., White, L., Baker, J., Venugopal, K., Tandon, B., Bryant, R. V. ... An, Y. K. (2026). Janus kinase inhibitors for acute severe ulcerative colitis: comparing upadacitinib to tofacitinib and rescue to sequential salvage therapy. Clinical Gastroenterology and Hepatology. doi: 10.1016/j.cgh.2026.09.017 |
|
2026 Journal Article The Burden of Viral Respiratory Infections in Immunosuppressed Inflammatory Bowel Disease PatientsHuynh, D., Khoo, E., Shanmuga Anandan, A. and Begun, J. (2026). The Burden of Viral Respiratory Infections in Immunosuppressed Inflammatory Bowel Disease Patients. JGH Open, 10 (8) e70456, e70456-e70456. doi: 10.1002/jgh3.70456 |
|
2026 Conference Publication Real-world quality of life, disability, and work productivity outcomes with ustekinumab in moderate-to-severe Crohn's disease: Results from an Australian prospective multicenter observational cohort studyMa, Xiaomin, An, Yoon-Kyo and Begun, Jakob (2026). Real-world quality of life, disability, and work productivity outcomes with ustekinumab in moderate-to-severe Crohn's disease: Results from an Australian prospective multicenter observational cohort study. HOBOKEN: WILEY. |
|
2026 Conference Publication Novel Bacteroides cellulosilyticus strain produces a small anti-inflammatory bioactive with therapeutic potential for inflammatory bowel diseaseMurtaza, Nida, Giri, Rabina, Schooth, Lauren, Salim, Angela, Capon, Rob, Morrison, Mark and Begun, Jakob (2026). Novel Bacteroides cellulosilyticus strain produces a small anti-inflammatory bioactive with therapeutic potential for inflammatory bowel disease. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2026, Perth, WA Australia, 28-31 August 2026. Richmond, VIC Australia: John Wiley & Sons. |
|
2026 Conference Publication Real-world effectiveness of upadacitinib for Crohn's disease: One-year outcomes from a multicenter cohort examining complex phenotypesGilmore, Robert, Goetz, Naeman, Yeo, Jeremy, Pham, Lily, Fernandes, Richard, Nguyen, Andrew, Vasudevan, Abhinav, Parkash, Nikita, Moore, Gregory, Christmas, Michael, White, Lauren, Subhaharan, Deloshaan, Ramaswamy, Pradeep, Mohsen, Waled, Massouridis, Benjamin, Sparrow, Miles, Lin, Alan, Clark, Nicholas, Ding, Nik, Lo, Sheng, De Cruz, Peter, Thin, Lena, Riley, Maddeson, Connor, Susan Jane, Lee, Adrian, Corte, Crispin, O'Hare, Rosie, Tan, Terrance, Etchegaray, Amirah ... Begun, Jakob (2026). Real-world effectiveness of upadacitinib for Crohn's disease: One-year outcomes from a multicenter cohort examining complex phenotypes. HOBOKEN: WILEY. |
|
2026 Conference Publication Upadacitinib versus oral corticosteroid for induction of remission in ulcerative colitis flares: INDUCE-A prospective, multicenter, open-label studyGilmore, Robert, Goetz, Naeman, An, Yoon-Kyo and Begun, Jakob (2026). Upadacitinib versus oral corticosteroid for induction of remission in ulcerative colitis flares: INDUCE-A prospective, multicenter, open-label study. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2026, Perth, WA, Australia, 28–31 August 2026. Richmond, VIC, Australia: John Wiley & Sons. |
|
2026 Conference Publication Evaluation of transmural healing in patients with moderately to severely active Crohn's disease shows early efficacy of vedolizumab: VECTORS week 14 interim analysisSparrow, Miles, Jairath, Vipul, Vuyyuru, Sudheer K., Ma, Christopher, Zou, Guangysong, Neustifter, Blue, Agboton, Christian, Bautista, Itzel Romo, Wu, Jingang Jackie, Jiang, Hongyu Jeanne, Allocca, Mariangela, An, Yoon-Kyo, Begun, Jakob, Bryant, Robert, Danese, Silvio, Dubinsky, Marla C., Freire, Marcelo, Novak, Kerri L., Panaccione, Remo, Pudipeddi, Aviv, Rubin, David T., Sands, Bruce E., Taylor, Stuart A., Gecse, Krisztina B., Maaser, Christian, Feagan, Brian G. and Wilkens, Rune (2026). Evaluation of transmural healing in patients with moderately to severely active Crohn's disease shows early efficacy of vedolizumab: VECTORS week 14 interim analysis. HOBOKEN: WILEY. |
|
2026 Conference Publication Challenging the indolent paradigm: Elderly acute severe ulcerative colitis has outcomes similar to younger cohortsKarunadasa, Hirannya, Mohamedrashed, Mustafa, O'Connor, Ronan, Fernandes, Richard Gareth, Ruddick-Collins, Leonie, Brownson, Anthony Robert, Ngoi, Benjamin, Haifer, Craig, Swe, Ei, Wright, Emily K., Mahy, Gillian, Moore, Gregory, Zhang, Jennifer, Lynch, Kate, Gazelakis, Kathryn, Rice, Katie, Bracken, Lucy Mary Lilian, Garg, Mayur, Schultz, Michael, Clark, Nicholas, Gilmore, Robert, Kashkooli, Soleiman, Schildkraut, Tamar, Begun, Jakob, An, Yoon-Kyo, Srinivasan, Ashish and Vasudevan, Abhinav (2026). Challenging the indolent paradigm: Elderly acute severe ulcerative colitis has outcomes similar to younger cohorts. HOBOKEN: WILEY. |
|
2026 Conference Publication Prescribing patterns and persistence of advanced therapies in people with ulcerative colitis who are bio-experienced: Insights from the Crohn's Colitis Care registryWu, Rodger, Ghali, Mark, Wilson, William, Caquilpan, Victor, Rivas, Consuelo, Lynch, Kate, Haifer, Craig, Walker, Gareth, Radford-Smith, Graham, Lawrance, Ian, Begun, Jakob, Wark, Gabrielle, Verdon, Christine, Andrews, Jane Mary, Ghaly, Simon and Connor, Susan Jane (2026). Prescribing patterns and persistence of advanced therapies in people with ulcerative colitis who are bio-experienced: Insights from the Crohn's Colitis Care registry. HOBOKEN: WILEY. |
|
2026 Conference Publication Serum calprotectin has limited utility as a biomarker of mucosal inflammation and remission in vedolizumab-treated ulcerative colitis: A post-hoc analysis of the VIEWS trialPajes, Nico, Pudipeddi, Aviv, Paramsothy, Sudarshan, Kariyawasam, Viraj, Gu, Bonita, Louie, Gary, Rayamajhee, Binod, Chami, Belal, Paramsothy, Ramesh, Ghaly, Simon, Haifer, Craig, An, Yoon-Kyo, Begun, Jakob, Connor, Susan Jane, Corte, Crispin, Ward, Mark, De Cruz, Peter, Fung, Caroline Lan-San, Redmond, Diane, Kermeen, Melissa, Chan, Webber, Mourad, Fadi H. and Leong, Rupert (2026). Serum calprotectin has limited utility as a biomarker of mucosal inflammation and remission in vedolizumab-treated ulcerative colitis: A post-hoc analysis of the VIEWS trial. HOBOKEN: WILEY. |
|
2026 Journal Article Study of TOfacitinib for the treatment of chronic PouchITis (STOPit): a multi-centre open label induction with randomised, double blind, placebo-controlled maintenance trialKhoo, Emi, Holtmann, Gerald and Begun, Jakob (2026). Study of TOfacitinib for the treatment of chronic PouchITis (STOPit): a multi-centre open label induction with randomised, double blind, placebo-controlled maintenance trial. BMJ Open, 16 (7) e118940, e118940-7. doi: 10.1136/bmjopen-2026-118940 |
|
2026 Journal Article New Diagnostic Criteria for Acute Severe Ulcerative Colitis in the Modern Treatment Era: A Modified Delphi Consensus by REFINED-ASUCRaine, Tim, Peyrin-Biroulet, Laurent, Begun, Jakob, Biedermann, Luc, Blumenstein, Irina, Cheifetz, Adam S., Colombel, Jean-Frederic, Dulai, Parambir S., Gecse, Krisztina B., Jairath, Vipul, Nakase, Hiroshi, Panaccione, Remo, Reinisch, Walter, Verstockt, Bram and Higgins, Peter D.R. (2026). New Diagnostic Criteria for Acute Severe Ulcerative Colitis in the Modern Treatment Era: A Modified Delphi Consensus by REFINED-ASUC. Clinical Gastroenterology and Hepatology. doi: 10.1016/j.cgh.2026.07.011 |
|
2026 Journal Article Acute severe ulcerative colitis patients from Asia have lower colectomy risk than patients from AustralasiaFernandes, Richard Gareth, Kim, Dong Hyun, Ruddick-Collins, Leonie, Vasudevan, Abhinav, Brownson, Anthony Robert, Ngoi, Benjamin, Lin, Chun-Chi, Haifer, Craig, Kim, Dae Sung, Swe, Ei, Wright, Emily Kate, Song, Eun Mi, Mahy, Gillian, Moore, Gregory Thomas, Lee, Hyun Seok, Kim, Hyun Soo, Zhang, Jennifer, Yan Mak, Joyce Wing, Lee, Jun, Lynch, Kate, Gazelakis, Kathryn, Rice, Katie, Kim, Kyeong Ok, Liu, Jing, Lilian Bracken, Lucy Mary, Garg, Mayur, Schultz, Michael, Clark, Nicholas, Cao, Qian ... An, Yoon-Kyo (2026). Acute severe ulcerative colitis patients from Asia have lower colectomy risk than patients from Australasia. Clinical Gastroenterology and Hepatology, 24 (7), 1916-1927. doi: 10.1016/j.cgh.2025.10.019 |
|
2026 Journal Article Never‐smoking is associated with histologic remission in ulcerative colitis: a post‐hoc analysis of the VIEWS randomised controlled trialPudipeddi, Aviv, Pajes, Nico, Paramsothy, Sudarshan, Kariyawasam, Viraj, Paramsothy, Ramesh, Ghaly, Simon, Haifer, Craig, An, Yoon‐Kyo, Begun, Jakob, Connor, Susan J., Corte, Crispin, Ward, Mark G., De Cruz, Peter, Fung, Caroline Lan‐San, Redmond, Diane, Chan, Webber, Mourad, Fadi H., Kermeen, Melissa and Leong, Rupert W. (2026). Never‐Smoking Is Associated With Histologic Remission in Ulcerative Colitis: A Post‐Hoc Analysis of the VIEWS Randomised Controlled Trial. JCC Plus, 1 (4) e70051. doi: 10.1002/jcc5.70051 |
|
2026 Journal Article Distinct predictive factors for acute severe ulcerative colitis in East Asian and Western populationsKim, Eun Soo, Kim, Dong Hyun, Kim, Seong-Jung, Park, Sang Hyoung, Lee, Hyun Seok, Kim, Sung Kook, Kim, Hyun Soo, Lee, Jun, Kim, Kyeong Ok, Jang, Byung Ik, Lee, Yoo Jin, Song, Eun Mi, Kim, Dae Sung, Lin, Chun-Chi, Mak, Joyce Wing Yan, Liu, Jing, Cao, Qian, Wei, Shu-Chen, Lin, Wei-Chen, Hsu, Wen-Hung, Sagami, Shintaro, Kobayashi, Taku, Fernandes, Richard G, Gilmore, Robert, An, Yoon-Kyo, Begun, Jakob, Rice, Katie, Ruddick-Collins, Leonie, Vasudevan, Abhinav ... Australia New Zealand IBD Consortium (ANZIBDC) and the Asian Organization for Crohn’s and Colitis (AOCC) (2026). Distinct predictive factors for acute severe ulcerative colitis in East Asian and Western populations. Inflammatory Bowel Diseases izag098. doi: 10.1093/ibd/izag098 |
|
2026 Conference Publication Sa1578 DIVIDED BY DISTANCE: INSIGHTS INTO REGIONAL DISPARITIES IN INFLAMMATORY BOWEL DISEASE CARE ACROSS AUSTRALIA FROM THE CROHN’S COLITIS CURE DATA INSIGHTS PROGRAMWu, Rodger, Caquilpan, Victor, Wilson, William E., Lynch, Kate D., Ng, Watson, Lawrance, Ian C., Radford-Smith, Graham, Walker, Gareth, Begun, Jakob, Moore, Gregory, Ghaly, Simon, Dutt, Shoma, Giles, Edward, Verdon, Christine, Andrews, Jane and Connor, Susan J. (2026). Sa1578 DIVIDED BY DISTANCE: INSIGHTS INTO REGIONAL DISPARITIES IN INFLAMMATORY BOWEL DISEASE CARE ACROSS AUSTRALIA FROM THE CROHN’S COLITIS CURE DATA INSIGHTS PROGRAM. Elsevier BV. doi: 10.1016/s0016-5085(26)02588-6 |
|
2026 Conference Publication Su1577 REAL-WORLD TRENDS IN SUBCUTANEOUS AND INTRAVENOUS INFLIXIMAB AND VEDOLIZUMAB USE IN INFLAMMATORY BOWEL DISEASE FROM 2021 TO 2024: INSIGHTS FROM CROHN’S COLITIS CURE DATA INSIGHTS PROGRAMWu, Rodger, Su, Wai Kin, Wilson, William E., Caquilpan, Victor, Lynch, Kate D., Wark, Gabrielle, Lawrance, Ian C., Begun, Jakob, Haifer, Craig, Radford-Smith, Graham, Walker, Gareth, Shahzad, Asif, Giles, Edward, Dutt, Shoma, Connor, Susan J. and Andrews, Jane (2026). Su1577 REAL-WORLD TRENDS IN SUBCUTANEOUS AND INTRAVENOUS INFLIXIMAB AND VEDOLIZUMAB USE IN INFLAMMATORY BOWEL DISEASE FROM 2021 TO 2024: INSIGHTS FROM CROHN’S COLITIS CURE DATA INSIGHTS PROGRAM. Elsevier BV. doi: 10.1016/s0016-5085(26)02784-8 |
|
2026 Conference Publication Mo1597 Prescribing patterns and persistence of advanced therapies in people with Crohn’s disease with prior advanced therapy: Crohn’s colitis cure data insights programGhali, Mark, Wu, Rodger, Wilson, William E., Caquilpan, Victor, Rivas, Consuelo, Haifer, Craig, Ng, Watson, Lynch, Kate D., Lawrance, Ian C., Begun, Jakob, Walker, Gareth, Radford-Smith, Graham, Shahzad, Asif, Boyapati, Ray, Verdon, Christine, Connor, Susan J., Andrews, Jane and Ghaly, Simon (2026). Mo1597 PRESCRIBING PATTERNS AND PERSISTENCE OF ADVANCED THERAPIES IN PEOPLE WITH CROHN’S DISEASE WITH PRIOR ADVANCED THERAPY: CROHN’S COLITIS CURE DATA INSIGHTS PROGRAM. Gastrointestinal Endoscopy, 103 (5), S-1204. doi: 10.1016/s0016-5107(26)02967-6 |
